Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500318 · ClinicalTrials.gov registry record · Phase 3
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 181
- Enrollment target
NCT00500318 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 181 participants.
The verdict
NCT00500318, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 181 participants
- Enrollment target
Study Summary
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.
Interventions
- DRUG Placebo
- DRUG Aclidinium Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500318
The ClinicalTrials.gov registry entry for NCT00500318 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00500318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500318 about?
NCT00500318 is a clinical study titled "A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week fol...
What is the current status of trial NCT00500318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 181 participants. The study started on 2007-07. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00500318?
The interventions under investigation include: Placebo (DRUG), Aclidinium Bromide (DRUG).
Who is sponsoring clinical trial NCT00500318?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.